Loading data...
Loading data...
Analyzing the stock…
70
Gathering technical, fundamental, and market data — a few seconds
Health Care · ·
$4.35
▼ $0.09 (-2.0%)
Market data updated: 09/19 01:03 PM
Fundamentals updated: 09/19/2026
News analyzed: 09/19/2026
Market Cap
$857.16M
Day Range
$4.31 - $4.48
52-Week Range
$4.31 - $21.73
Beta
—
Next Earnings
09.11.2026
Support
$4.40
Resistance
$6.41
WVE is a stock from the Healthcare sector — Pharmaceuticals, biotech, medical devices, and health insurance — less sensitive to economic cycles, but exposed to regulation and FDA approvals.
-34.7% (1Y)
Strengths: 3/27 factors positiveRisk: High
This score and all analysis on this page are for informational and educational purposes only and do not constitute investment advice. Read the full disclaimer
Weighted: Technical 25% · Fundamental 20% · Growth 15% · Valuation 15% · News 10% · Quality 10% · Risk 5%
Overall Score
🔴 Bearish
Technical Trend
🔴 Bearish
Insiders
🟡 Mixed
Computed directly from the same signals behind the score above — not AI-generated.
Biggest positive driver
Operating margin stability
Operating margin is stable or improving over time
Quality
Biggest negative driver
DCF Fair Value
Estimated fair value: -$28.48 vs. price $4.35 (-754.6%)
Fair Value
What to watch next
When today echoes the past.
NO RELIABLE ECHO FOUND
Only 2 historical analog(s) found after removing overlapping dates — too few for a statistically meaningful comparison.
Historical matches considered: 2
TIME ECHO identifies historical situations that resemble the current market state. Historical outcomes are not guarantees of future performance. Similarity does not imply causation, and results may change as new data becomes available.
🗓️ What Changed This Week
🌱 Building History
We don't have a real data point from a week ago for this stock yet. The weekly comparison will appear once enough history has accumulated.
📊 Score History
29
Today
—
30D
—
90D
—
1Y
🐂🐻 Investment Thesis
🐂 Bull Case
🐻 Bear Case
🔍 What Could Prove This Wrong
This isn't a price-direction forecast — just a synthesis of real, already-computed data, and future conditions that could change the picture.
🧬 STOCK DNA
This stock's profile across 8 real dimensions — a research tool, not a recommendation
Growth
26
Quality
58
Value
38
Momentum
9
Risk
40
Sentiment
32
Fundamental
30
Institutional
50
Stocks with a similar DNA right now
This stock hasn't been analyzed by StockIQAI's movement engine yet — coverage is still expanding. Check back soon.
Recent media coverage of Wave Life Sciences Ltd. has centered on its strategic shifts and financial updates. The company announced its redomiciliation from Singapore to Delaware, a move that could influence its regulatory and investor landscape. Financial reports highlighted mixed first-half 2026 results, with modest revenue growth but persistent losses. Analysts have also discussed its potential appeal to pharmaceutical acquirers, citing its RNA medicine focus and valuation as key factors. Upcoming presentations at major conferences, like the Cantor Global Healthcare Conference, suggest continued investor engagement.
AI summary based on English-language news sources only — not investment advice.
Everyone's writing about Wave Life Sciences Ltd.. News trend score: 32. Reason: 5 of the last 20 articles are negative, versus 2 positive.
News trend analysis is based on article sentiment only, and is not investment advice or financial counsel. Read the full disclaimer
🌡️ Emotional Temperature
27
🎯 Conviction (vs. Emotion)
24
Psychology
82
Fundamentals
30
Technical
9
Valuation
38
The price is holding at a real, documented historical support/resistance level (a 50-day high or low).
A significant decline over time, but on unusually low trading volume — holders unwilling to accept the loss.
The stock is moving in lockstep with its peers at the same intensity, rather than on its own data.
A sharp drop, unusual volume, and negative news sentiment all at once — selling pressure that looks emotional.
Price, volume, and sentiment accelerating together — a sign investors are chasing the price, not just following it.
Price (3M)
-28%
Market Narrative
26
Fundamental Reality
24
Narrative Gap
+2
🔀 Psychology Acceleration
News attention/sentiment is running well ahead of the price move itself.
🧠 StockIQ Psychologist
WVE’s psychology profile reflects a mixed but cautious environment, with **loss aversion** (24) and **panic selling** (26) as dominant forces. The 3-month drawdown (-13.3%) and elevated volume suggest traders are hesitant to crystallize losses, while the lack of extreme volatility (0.92x ATR) implies selling is measured rather than frantic. The narrative gap (5) hints at a disconnect between market expectations and reality, but the absence of euphoria or herding suggests no blind optimism or herd-driven moves. The key question: *Will traders exit gradually or accelerate selling if momentum worsens?*
Updated: 09/09/2026, 09:40 AM
What could change this?
👥 What the crowd believes
"Wave Life Sciences to Present at Cantor 2026 Global Healthcare Conference"
"Wave Life Sciences Completes Redomiciliation to Delaware"
"Wave Life Sciences Ltd. reported second-quarter 2026 results ... net loss of US$69.36 million"
"Wave Life Sciences: A $1 Billion RNA-Medicine Bargain Ripe for Pharma Takeover"
📈 9D Investor Psychology
Signal classification confidence: High (confidence in the behavioral read, not a price prediction). Describes observable market behavior, not what any individual investor thinks, and is not a buy/sell signal.
🏛️ Investor DNA — Historical Investors
A Historical Strategy Simulation: assuming each investor follows their documented principles, how would they rate this stock today? This is not a prediction of what they would actually do.
🟢 Best match
Charles Mackay — 100/100
🔴 Weakest match
Morgan Housel — 0/100
🗣️ Why do they disagree?
This stock’s starkly divided verdicts reflect a deep split between methodologies that prioritize macro resilience and cyclical positioning versus those demanding intrinsic value, growth, or trend alignment. The highest-scoring approaches—from Mackay’s crowd psychology, Bagehot’s liquidity focus, and Marks’ cycle analysis—suggest WVE avoids speculative bubbles and credit risks, fitting a defensive or contrarian mindset. Meanwhile, the lowest scores cluster around Fisher, Lynch, and Housel, who all demand clear growth momentum, patient long-term stability, or volatility tolerance—qualities the stock fails to exhibit. Even Graham’s Defensive Investor sees value, but his Enterprising counterpart flags it as too shallow a bargain, illustrating how valuation thresholds vary wildly. The divide underscores whether one trusts structural soundness (high scores) or fundamental growth (low scores) as the primary filter.
Charles Mackay
Extraordinary Popular Delusions and the Madness of Crowds (1841)
🟢 100
No obvious signs of crowd mania
Key question
Am I being swept along with the crowd, or thinking for myself?
Fact → Principle → Simulation
Walter Bagehot
Lombard Street (1873)
🟢 100
Strong liquidity — would likely survive a real credit squeeze
Key question
Does this company have enough liquidity to survive real stress?
Fact → Principle → Simulation
Howard Marks (Market Cycle)
Mastering the Market Cycle (2018)
🟢 100
Looks early-to-mid cycle, not overextended
Key question
Where are we in the cycle right now — near a hot extreme, or a cold one?
Fact → Principle → Simulation
Samuel Armstrong Nelson
The ABC of Stock Speculation (1903)
🟢 99
Cycle position looks favorable — closer to oversold than overbought
Key question
Is the price overextended, or is there still room to move?
Fact → Principle → Simulation
Benjamin Graham
Security Analysis (1934) / The Intelligent Investor (1949)
🟢 88
Attractive to a Defensive Graham Investor
Key question
Where is my margin of safety?
⚠️ Partial data for this stock — score is less reliable — Data availability: 35%
Fact → Principle → Simulation
Jack Schwager
Market Wizards (1989)
🟢 76
A real, disciplined setup with favorable reward/risk
Key question
What's the risk/reward here, and where is my exit point?
Fact → Principle → Simulation
Howard Marks
The Most Important Thing (2011) / Mastering the Market Cycle (2018)
🟢 72
Risk appears reasonably priced — no obvious cycle-timing red flag
Key question
What is the market probably misunderstanding about the risk here?
Fact → Principle → Simulation
Benjamin Graham (Enterprising Investor)
The Intelligent Investor (1949) — the Enterprising Investor chapters
🟢 66
Some discount, but not the deep 'net-net' bargain Graham's enterprising bar sets
Key question
Is the stock statistically cheap enough to justify the extra risk?
⚠️ Partial data for this stock — score is less reliable — Data availability: 45%
Fact → Principle → Simulation
Gerald M. Loeb
The Battle for Investment Survival (1935)
🟡 39
Risk profile Loeb would flag as a real threat to capital
Key question
How much capital could I lose here if I'm wrong?
Fact → Principle → Simulation
Thorstein Veblen
The Theory of Business Enterprise (1904)
🔴 30
Pattern Veblen would flag as growth pursued for its own sake
Key question
Is management building real value, or just building itself?
Fact → Principle → Simulation
Edgar Lawrence Smith
Common Stocks as Long-Term Investments (1924)
🔴 30
Doesn't show the stability Smith's long-term case requires
Key question
Is this a stock I'd be happy to hold and forget about for a decade?
Fact → Principle → Simulation
Burton Malkiel & John Bogle
A Random Walk Down Wall Street (1973) / The Little Book of Common Sense Investing (2007)
🔴 27
Weak case — Malkiel/Bogle would say a low-cost index is the simpler bet
Key question
Do I actually have an edge here, or do I just think I do?
Fact → Principle → Simulation
Jesse Livermore
Reminiscences of a Stock Operator (1923) / How to Trade in Stocks (1940)
🔴 27
Negative trend — against Livermore's core rule of trading with the trend
Key question
What is the price telling me right now?
Fact → Principle → Simulation
Philip Fisher
Common Stocks and Uncommon Profits (1958)
🔴 21
Doesn't show the quality/growth signature Fisher required
Key question
How exceptional is this business, really?
Fact → Principle → Simulation
Peter Lynch
One Up on Wall Street (1989)
🔴 20
Doesn't clear Lynch's growth-at-a-reasonable-price bar
Key question
Is the growth worth the price?
Fact → Principle → Simulation
Morgan Housel
The Psychology of Money (2020)
🔴 0
The kind of volatility that tends to shake patient holders out
Key question
Could I live with this volatility long enough for compounding to actually work?
Fact → Principle → Simulation
Based on the last 279 trading days, calculated from real price data. Click an indicator for details and a chart.
🔴 Most indicators support a downtrend (0 bullish · 11 bearish · 0 neutral)
A market-structure read based purely on real price and volume data — not full classic Wyckoff schematic identification (Phase A-E), but a quantitative analysis of what can reliably be computed: trading ranges, "effort vs. result", volume within the range, and Spring/Upthrust detection.
The stock is in a clear downtrend with no defined trading range in the period examined.
Medium confidence
The Wyckoff Method, developed by Richard Wyckoff in the early 20th century, reads the balance of supply and demand through price and volume, based on the premise that large investors ("smart money") quietly accumulate shares before rallies and quietly distribute them before declines. The read here is based solely on real price and volume data — full, precise identification of classic Wyckoff patterns (such as Phases A-E) requires human chart-reading experience and judgment, so this is an approximate algorithmic read, not a substitute for professional analysis. This should not be considered investment advice.
Gross Margin
—
Operating Margin
-504.1%
Net Margin
-478.3%
EBITDA Margin
-504.1%
ROE
-39.4%
ROA
-32.0%
ROIC
—
EPS
-$1.21
Cash
$602.07M
Total Debt
—
Current Ratio
6.47
Debt/Equity
—
How is Fair Value calculated? →
Current Price
$4.35
Estimated Fair Value (DCF)
-$28.48
Model estimate — not a price target. Highly sensitive to growth/discount-rate assumptions.
Gap
-754.6%
🔴 Appears expensive relative to estimated value
Year 1 Growth Rate
25.0%
Discount Rate (WACC)
9.0%
Terminal Growth Rate
2.5%
Projection Years
5
| Year | Growth Rate | Projected FCF | Present Value |
|---|---|---|---|
| 1 | 25.0% | $-235.26M | $-215.84M |
| 2 | 19.4% | $-280.85M | $-236.38M |
| 3 | 13.8% | $-319.46M | $-246.68M |
| 4 | 8.1% | $-345.42M | $-244.70M |
| 5 | 2.5% | $-354.05M | $-230.11M |
Base FCF (last actual year)
$-188.21M
Terminal Value
$-5.58B
Present Value of Terminal Value
$-3.63B
Enterprise Value
$-4.80B
Net Debt
$0
Equity Value
$-4.80B
*The DCF model is an estimate based on assumptions — not a guaranteed forecast. You can change the assumptions to examine different scenarios.
Book Value per Share
$3.07
Tangible Book Value per Share (Tangible NAV)
$3.07
Sentiment based on basic keywords (not AI) — 2 positive, 13 neutral, 5 negative out of the last 20 articles.
GlobeNewswire · 3.9.2026
Yahoo · 3.9.2026
24/7 Wall St. · 13.8.2026
SeekingAlpha · 12.8.2026
SeekingAlpha · 11.8.2026
SeekingAlpha · 11.8.2026
MT Newswires · 10.8.2026
Simply Wall St. · 7.8.2026
Yahoo · 7.8.2026
GlobeNewswire · 5.8.2026
Yahoo · 5.8.2026
GlobeNewswire · 4.8.2026
Benzinga · 4.8.2026
Yahoo · 4.8.2026
Motley Fool · 4.8.2026
Yahoo · 3.8.2026
Benzinga · 31.7.2026
MT Newswires · 31.7.2026
Benzinga · 31.7.2026
Benzinga · 31.7.2026
Wave Life Sciences Ltd. (WVE) currently has a StockIQ AI score of 29/100, rated "Weak". The score is a weighted average across up to 7 categories (technical, fundamental, growth, fair value, news, quality, risk), based on real data only.
WVE currently scores 29/100 (Weak) across the categories we measure. StockIQ doesn't give buy/sell recommendations — use this as one data point in your own research, not as investment advice.
Per StockIQ's DCF model, WVE's estimated fair value is -$28.48, which is 754.6% below the current price of $4.35. This is one valuation model among several signals in the fair-value category, not a price target.
WVE's technical score is 9/100, which currently reads as bearish — based on real price/volume signals (moving averages, RSI, MACD, and more), not a prediction of what happens next.
Based on the real signals StockIQ computed: Operating margin is stable or improving over time; Current ratio: 6.47; Current ratio: 6.47.
Based on the real signals StockIQ computed: Estimated fair value: -$28.48 vs. price $4.35 (-754.6%); Operating margin: -504.1% (negative); Net margin: -478.3% (negative).
StockIQ has no recorded dividend payment history for WVE.
Real transactions by officers and insiders, as reported to the SEC on Form 4 — 8 purchases and 8 sales out of the last 25 filings.
| Name | Transaction Type | Date | Shares | Change | Price |
|---|---|---|---|---|---|
| Rawcliffe Adrian | Open Market Sale | 12.8.2026 | 12,700 | -12,700 | $5.29 |
| Rawcliffe Adrian | Open Market Sale | 12.8.2026 | 0 | -12,700 | $5.29 |
| Tan Aik Na | Open Market Sale | 11.8.2026 | 432 | -432 | $6.01 |
| Wagner Heidi L | Exercise of Derivative Securities | 11.8.2026 | 7,000 | +7,000 | $5.97 |
| TAKANASHI KEN | Open Market Sale | 11.8.2026 | 3,864 | -3,864 | $6.01 |
| Wagner Heidi L | Exercise of Derivative Securities | 11.8.2026 | 7,000 | -7,000 | — |
| Wagner Heidi L | Open Market Sale | 11.8.2026 | 7,000 | -7,000 | $6.01 |
| Tan Aik Na | Open Market Sale | 11.8.2026 | 24,968 | -432 | $6.01 |
| TAKANASHI KEN | Open Market Sale | 11.8.2026 | 20,079 | -3,864 | $6.01 |
| Wagner Heidi L | Exercise of Derivative Securities | 11.8.2026 | 51,930 | +7,000 | $5.97 |
| Wagner Heidi L | Open Market Sale | 11.8.2026 | 44,930 | -7,000 | $6.01 |
| Wagner Heidi L | Exercise of Derivative Securities | 11.8.2026 | 0 | -7,000 | — |
| RA CAPITAL MANAGEMENT, L.P. | Open Market Purchase | 30.3.2026 | 971,091 | +971,091 | $6.50 |
| RA Capital Healthcare Fund LP | Open Market Purchase | 30.3.2026 | 26,975,505 | +971,091 | $6.50 |
| RA CAPITAL MANAGEMENT, L.P. | Open Market Purchase | 27.3.2026 | 2,495,623 | +2,495,623 | $6.43 |
| RA Capital Healthcare Fund LP | Open Market Purchase | 27.3.2026 | 26,004,414 | +2,495,623 | $6.43 |
| RA CAPITAL MANAGEMENT, L.P. | Open Market Purchase | 26.3.2026 | 4,954,558 | +4,954,558 | $6.06 |
| RA CAPITAL MANAGEMENT, L.P. | Open Market Purchase | 26.3.2026 | 351,224 | +351,224 | $6.38 |
| RA Capital Healthcare Fund LP | Open Market Purchase | 26.3.2026 | 23,157,567 | +4,954,558 | $6.06 |
| RA Capital Healthcare Fund LP | Open Market Purchase | 26.3.2026 | 23,508,791 | +351,224 | $6.38 |
| TAKANASHI KEN | Conversion of Derivative Security | 23.3.2026 | 3,901,348 | -3,901,348 | — |
| TAKANASHI KEN | Conversion of Derivative Security | 23.3.2026 | 3,901,348 | +3,901,348 | — |
| TAKANASHI KEN | Conversion of Derivative Security | 23.3.2026 | 9,606,408 | +3,901,348 | — |
| TAKANASHI KEN | Conversion of Derivative Security | 23.3.2026 | 0 | -3,901,348 | — |
| Francis Chris | Exercise of Derivative Securities | 26.2.2026 | 17,900 | -17,900 | — |
Official FINRA data — the number of shares open in short positions, plus daily short-sale activity.
16,281,873 shares short as of 2026-08-31 · vs. 16,401,737 on 2026-07-31
Official biweekly report (FINRA Rule 4560) — no real higher-frequency data exists for this metric.
43.3% of trading volume this week was short selling, vs. 47.0% the prior week
Based on daily short-sale volume (Reg SHO) — a different metric from the open short interest above: this is daily trading volume, not an open position, so it updates weekly rather than biweekly.
Full breakdown of every data type and its source: Data Sources · Methodology